Oramed Pharmaceuticals
Transforming Injectables into Oral Therapies
StartupOramed Pharmaceuticals is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2006. Transforming Injectables into Oral Therapies. The company has raised a total of $149.13M across 10 funding rounds, currently at the Public stage. Oramed Pharmaceuticals was founded by Nadav Kidron and Miriam Kidron. Key investors include Undisclosed Investor(s), Hefei Tianhui Incubator of Technologies, Guangxi Wuzhou Pharmaceutical Group. The company has 11-50 employees. Core technologies: Biologicals, Molecules.
With $149.13M in total funding, Oramed Pharmaceuticals is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B/B2C/B2B2C/B2G business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B, B2C, B2B2C, B2G
- Employees11-50
- HQJerusalem
- DistrictJerusalem District
- Last Round$50M
- Undisclosed Investor(s)
- Hefei Tianhui Incubator of Technologies
- Guangxi Wuzhou Pharmaceutical Group
Nadav KidronCo-founder, CEO, President & Director
Miriam KidronCo-founder, CSO & Director
104 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
www.biopharma-reporter.com,
oramed.com,
nocamels.com.
What does Oramed Pharmaceuticals do?
Oramed Pharmaceuticals has developed a proprietary platform technology that allows for the oral delivery of drugs currently administered only via injection. The company's flagship product is an oral insulin capsule that has the potential to better the lives of millions of diabetics worldwide by enabling patients with type 2 diabetes to begin insulin therapy earlier, without needles. Oramed's oral insulin is in advanced phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes. In addition to oral insulin, the company's proprietary POD technology can potentially be used to orally administer a number of protein-based therapies that are presently available only via injection.
How much funding has Oramed Pharmaceuticals raised?
Oramed Pharmaceuticals has raised $149.13M in total funding across 10 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), Hefei Tianhui Incubator of Technologies, Guangxi Wuzhou Pharmaceutical Group.
Who founded Oramed Pharmaceuticals?
Oramed Pharmaceuticals was founded in 2006 by Nadav Kidron (Co-founder, CEO, President & Director), Miriam Kidron (Co-founder, CSO & Director).
What sector is Oramed Pharmaceuticals in?
Oramed Pharmaceuticals operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is Oramed Pharmaceuticals located?
Oramed Pharmaceuticals is based in Mamilla Road 20, Jerusalem, Jerusalem District. The company also has offices abroad.